Project results are expected to contribute to all of the following expected outcomes for one of the areas:

Area 1: research infrastructure services to support research and development of medical countermeasures for epidemic response:

• Excellent research and innovation to identify, characterise and mitigate the effects of existing and future emerging pathogens of public health concern.
• Comprehensive catalogue of research infrastructure services relevant to tackle infectious diseases epidemics, updated and available.
• Increased knowledge on, and development of intervention tools against (re)emerging pathogens enabled by relevant research infrastructure services.
• Availability of research data emerging from access provision activities for re-use on common data platforms and registries, according to FAIR principles and compliant with legal provisions under the General Data Protection Regulation (GDPR).
• Challenge driven integration of EU research infrastructures and organisational and structural alignment with the future Pandemic Preparedness Partnership, the EU Reference Laboratories and the EU4Health funded laboratory network DURABLE (or relevant legacy initiative).
• Providing a long-term sustainability concept for such a research infrastructure network supporting epidemic research.

Area 2: research infrastructure services for improving clinical research in the paediatric area:

• Advancement of paediatric medicines and other therapeutic and diagnostic approaches for this population group to markets and towards clinical use;
• Accelerated availability of solutions and products to paediatric patients in need;
• Wider access to rationally designed research infrastructure services across Europe to underpin the competitiveness of the European industry and of biotech SMEs developing paediatric medicines and treatment and diagnostic devices;
• Joined forces of research infrastructures and paediatric competence networks in EU Member States and Associated Countries, to facilitate paediatric research in the context of pertinent EU regulatory environment;
• Availability of innovative tools to conduct paediatric clinical trials, for the re-use of population and historical data, and for enhanced data sharing across actors at different care levels and across regions in Europe.

Area 3: research infrastructure services to enable research linking environmental factors to human health:

• Better risk assessment tools and data evidence to anticipate and mitigate negative environmental implications on human health;
• Evidence to inform policy making and public health bodies with respect to assessment and management of environmental risks for human health;
• Wider access to specialised research infrastructure services to underpin the competitiveness of the European industry including SMEs active in the field of risk assessment and management of environmental impact on human health.
• Link with the environmental research on the exposure to other living organisms within the One-Health concept.